Roche expects its risdiplam medicine for spinal muscular atrophy (SMA) to get U.S. approval by May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area. The U.S. Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder. Roche, whose drug is seen as a rival for Biogen’s Spinraza and Novartis’s Zolgensma gene therapy, said the FDA is due to decide by May 24. …read more
Source:: Yahoo Finance
